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Abstract
Introduction: Potassium voltage-gated channel shaker-related subfamily member 5 (KCNA5) is implicated in
vascular tone regulation, and its inhibition during hypoxia produces pulmonary vasoconstriction. Recently, a
protective association of the KCNA5 locus with systemic sclerosis (SSc) patients with pulmonary arterial
hypertension (PAH) was reported. Hence, the aim of this study was to replicate these findings in an independent
multicenter Caucasian SSc cohort.
Methods: The 2,343 SSc cases (179 PAH positive, confirmed by right-heart catheterization) and 2,690 matched
healthy controls from five European countries were included in this study. Rs10744676 single-nucleotide
polymorphism (SNP) was genotyped by using a TaqMan SNP genotyping assay.
Results: Individual population analyses of the selected KCNA5 genetic variant did not show significant association
with SSc or any of the defined subsets (for example, limited cutaneous SSc, diffuse cutaneous SSc, anti-centromere
autoantibody positive and anti-topoisomerase autoantibody positive). Furthermore, pooled analyses revealed no
significant evidence of association with the disease or any of the subsets, not even the PAH-positive group. The
comparison of PAH-positive patients with PAH-negative patients showed no significant differences among patients.
Conclusions: Our data do not support an important role of KCNA5 as an SSc-susceptibility factor or as a PAH-
development genetic marker for SSc patients.
Introduction
Systemic sclerosis (SSc) is a life-threatening fibrotic con-
nective tissue disorder that affects the skin and different
internal organs [1]. The 10-year survival of SSc patients
reaches only 63%, with pulmonary involvement the leading
cause of death [2]. SSc is a complex disorder in which the
environmental triggers and genetic susceptibility factors
co-act in the development and maintenance of the disease
[3]. As a clearer picture of the genetic component of this
disease is being revealed, interest in genetic markers for
specific clinical features, especially lung involvement, is
increasing. An SSc phenotype-restricted genome-wide
analysis was carried out recently [4]. Remarkably, two of
the four new SSc genetic-susceptibility markers identified
in the previously mentioned study might play a relevant
role in the SSc-related fibrotic process, SOX5 and
NOTCH4 [4]. However, no such strategy has yet been con-
sidered for pulmonary involvement, and only some studies
have reported significant genetic association with SSc-
related lung involvement [5-9]. Furthermore, only the
association of CD226 with pulmonary fibrosis has been
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independently replicated [10]. Wipff et al. [11] recently
described the association of potassium voltage-gated chan-
nel shaker-related subfamily member 5 (KCNA5) with
SSc-related pulmonary arterial hypertension (PAH).
Potassium voltage-gated channels (Kv channels) are
homo- or heterotetramers of structural a-subunits and
regulatory b-subunits, which control potassium (K) flux. K
balance is known to regulate the apoptotic cell shrinkage,
a main event in the apoptotic process [12]. Specifically,
KCNA5 participates in pulmonary artery smooth muscle
cell (PASMC) apoptosis control [13]. It has been reported
that overexpression of the KCNA5 gene induces acceler-
ated K efflux and increases caspase-3 proteolytic activity,
promoting apoptosis [13].
KCNA5 is also involved in membrane-potential mainte-
nance and vascular-tone regulation [14]. Hypoxic condi-
tions produce a specific inhibition of KCNA5 in the
PASMCs, causing pulmonary vasoconstriction [15-17].
Moreover, it has been reported that primary pulmonary
hypertension patients have an intrinsic reduced level of
KCNA5 mRNA in their PASMCs, and this characteristic
might play an important role in the pathogenesis of the
disease [18].
The role of KCNA5 genetic polymorphisms in pulmon-
ary disease also was explored. Remillard et al. [19]
analyzed the influence of KCNA5 genetic variants in
IPAH, and showed that different single-nucleotide poly-
morphisms (SNPs) were related to abnormal function or
drug responsiveness. Recently, the importance of KCNA5
variants in SSc-related PAH was analyzed [11]. In the pre-
viously mentioned study, the association of KCNA5 with
SSc and specifically with PAH-positive (PAH+) patients
was described [11]. Moreover, the rs10744676 polymorph-
ism was reported as the variant underlying the observed
association [11].
In light of the previous evidence, the main goal of
this report is to replicate the association of KCNA5
rs10744676 polymorphism with SSc and SSc-related PAH
in an independent European population of Caucasian
ancestry.
Materials and methods
Subjects
Our study comprised 2,343 SSc cases and 2,690 controls
from Spain, The Netherlands, Italy, Sweden, and The
United Kingdom. All the individuals included in this
report were of Caucasian ancestry. Patients were classi-
fied as having limited (lcSSc) or diffuse SSc (dcSSc),
according to their skin involvement, as defined by
LeRoy et al. [20]. The serologic subgroup stratification
of the patients was based on the presence of SSc-asso-
ciated autoantibodies (anti-centromere antibodies
(ACAs) and anti-topoisomerase (ATA)). Pulmonary
fibrosis was diagnosed by the presence of interstitial
abnormalities in high-resolution computed tomography
(HRCT). Patients defined as PAH+ showed a mean rest-
ing pulmonary artery pressure > 25 mm Hg and a pul-
monary capillary wedge pressure ≤15 mm Hg, at the
time of a right-heart catheterization [11]. The control
population consisted of unrelated healthy individuals
recruited in the same geographic regions as the SSc
patients and matched by age, sex, and ethnicity with the
SSc-patient groups. Approval of local ethical committees
was obtained from all the participating centers (Comité
de Bioética del Consejo Superior de Investigaciones
Científicas, Comitato Etico Azienda Ospedaliera Univer-
sitaria Integrata di Verona, Local Ethics Committee of
the Radboud University Nijmegen Medical Centre, Med-
ische Ethische Commissie Leids Universitair Medisch
Centrum, The regional Ethical Review Board in Lund,
Local Research Ethics Committee at Glasgow Royal
Infirmary, U.O. Comitato di Etica e Sperimentazione
Farmaci Fondazione IRCCS Ca’ Granda-Ospedale Mag-
giore Policlinico di Milano, Local Research Ethics Com-
mittee at Glasgow Royal Infirmary, Royal Free Hospital
and Medical School Research Ethics Committee, Man-
chester University Research Ethics Committee). Written
informed consent was required for both patients and
controls to be included in the study.
Genotyping and statistical analysis
The rs10744676 KCNA5 biallelic variant was analyzed
with TaqMan SNP genotyping assay in a 7900HT Real-
Time polymerase chain reaction (PCR) system from
Applied Biosystems by following the manufacturer’s sug-
gestions (Foster City, CA, USA).
None of the included cohorts showed significant devia-
tion from Hardy-Weinberg equilibrium (HWE) (P value
significance threshold, 0.05). Significance for the allelic
model in the individual cohort analyses was calculated by
2 × 2 contingency tables and the Fisher Exact test or c2
when necessary. Odds ratios (ORs) were calculated
according to the Woolf method. A Breslow-Day test (BD
test) was performed to assess the homogeneity of the asso-
ciation among populations, and pooled analysis under a
Cochran-Mantel-Haenszel fixed-effect model was used to
analyze jointly all the included cohorts. Statistical analyses
were performed as implemented in PLINK (v1. 07) soft-
ware package [21]. Power was calculated by using the soft-
ware Power Calculator for Genetic Studies 2006 and
assuming an additive model and previously reported
minor allele frequency (MAF) and ORs [22].
Results
The power of our replication study in each stratified analy-
sis is summarized in Table 1. We emphasize that the size
of our pooled PAH+ patient subgroup represents the lar-
gest SSc-related PAH+ cohort analyzed to date (n = 179).
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The power of the study of this clinical feature in our popu-
lation to detect an association equivalent to that previously
reported by Wipff et al. is 95%, at the 5% significance level.
Table 2 shows the results of the comparison of the
complete set of SSc and each of the previously defined
subgroups with the healthy control group. As observed in
the table, the analyzed polymorphism showed no signifi-
cant association with either the disease or any of the sub-
sets, not even the PAH-positive group. Furthermore, no
significant association was observed in the individual
population analyses, either in the whole disease compari-
son or in the different subphenotypes (see Additional file
1, Table S1). The different cohorts showed a high inter-
population combinability, as can be observed in the Bre-
slow-Day test results (Table 2).
The minor allele in the Spanish and Italian control
populations included in this study was less frequent
than that in the pooled population described by the
Wipff et al. (rs10744676*C FrequencySpain = 10.48%;
rs10744676*C FrequencyItaly = 10.00%; rs10744676*C
Frequencypooled_Wipff = 14.7%). However, these frequen-
cies are in concordance with those reported for the
HapMap CEU population (MAFHapMap_CEU = 10.00%).
Moreover, MAF differences have been reported in
different European populations (MAF1000Genomes_CEU =
17.64%, MAF1000Genomes_GBR = 15.73%, MAF1000Genomes
_FIN = 13.98%, MAF1000Genomes_TSI = 8.16%).
In addition, the analysis of PAH+ versus PAH- patients
revealed no phenotype-restricted association in this sub-
group (PMH = 0.59; OR, 0.91; 95% CI, 0.64 to 1.28).
Discussion
Despite the previous findings of an association of the
rs10744676 KCNA5 genetic variant with PAH+ SSc
patients, our data do not corroborate the reported pro-
tective effect of the minor allele of this polymorphism
on SSc-related PAH.
It is worth mentioning that the prevalence of right-heart
catheterization-confirmed PAH in our pooled population
(7.64%) is consistent with previous reports [11]. However,
SSc is a chronic progressive disease, and some patients
classified as PAH- might develop PAH in the future.
Therefore, we consider this issue a limitation of our study
and similar reports. In this context, we point out that the
mean disease duration for the patient group included in
this study (mean disease duration, 13.9 ± 14.4 years, as
reported in Bossini-Castillo et al. [23]) was higher than
that in Wipff et al. [11] (11.9 ± 9.4 years in the discovery
Table 1 Overall statistical power of the study for KCNA5 rs10744676 SNP in each analyzed disease subtype at the 5%
significance level assuming an additive effect model and a minor allele (rs10744676*C) frequency = 0.10 (MAFCEU)
Phenotype
Statistical power (%) SSc lcSSc dcSSc ACA+ ATA+ Fib+ PAH+
OR = 0.62 100 100 99 100 96 99 95a
OR = 0.48 100 100 100 100 100 100 100b
OR = 0.79 96 91 67 77 59 71 45c
aReference OR, 0.62, except for the PAH+ group, in which OR = 0.47. bReference OR (lower previously reported 95% CI) = 0.48, except for the PAH+ group, in
which OR = 0.32. cReference OR (upper previously reported 95% CI) = 0.79, except for the PAH+ group, in which OR = 0.71. SSc, systemic sclerosis; lcSSc, limited
cutaneous systemic sclerosis; dcSSc, diffuse cutaneous systemic sclerosis; ACA+, anti-centromere autoantibody-positive patients; ATA+, anti-topoisomerase
autoantibody-positive patients; Fib+, lung fibrosis-positive patients (HRCT); PAH+, pulmonary arterial hypertension-positive patients (right-heart catheterization).
Table 2 Pooled analysis and stratified analyses of SSc patients and healthy controls for rs10744676 genetic variant,
located in the KCNA5 gene
Genotype, n (%) Allele test
Subgroup (n) C/C C/T T/T MAF (%) PMH OR (95% CI) PBD
Controls (n = 2,690) 37 (1.38) 597 (22.19) 2,056 (76.43) 12.47
SSc (n = 2,343) 43 (1.84) 471 (20.10) 1,829 (78.06) 11.89 0.49 0.96 (0.85-1.08) 0.53
lcSSc (n = 1,642) 31 (1.89) 327 (19.91) 1,284 (78.20) 11.85 0.48 0.95 (0.83-1.09) 0.63
dcSSc (n = 701) 12 (1.71) 144 (20.54) 545 (77.75) 11.98 0.80 0.98 (0.81-1.17) 0.59
ACA+ (n = 931) 18 (1.93) 197 (21.16) 716 (76.91) 12.51 0.49 1.06 (0.90-1.24) 0.96
ATA+ (n = 568) 8 (1.41) 117 (20.60) 443 (77.99) 11.71 0.85 0.98 (0.80-1.20) 0.94
Fib+ (n = 771) 14 (1.82) 154 (19.97) 603 (78.21) 11.80 0.34 0.92 (0.77-1.09) 0.92
PAH+ (n = 179) 2 (1.12) 37 (20.67) 140 (78.21) 11.45 0.44 0.88 (0.63-1.23) 0.70
MAF, minor allele frequency; PMH, Mantel-Haenszel test under fixed-effect P values. Controls are used as reference for all comparisons, and P values have been
calculated for the allelic model. OR, odds ratio for the minor allele; 95% CI, 95% confidence interval; SSc, systemic sclerosis; lcSSc, limited cutaneous systemic
sclerosis; dcSSc, diffuse cutaneous systemic sclerosis; ACA+, anti-centromere autoantibody-positive patient; ATA+, anti-topoisomerase autoantibody-positive
patient; Fib+, lung fibrosis-positive patient (HRCT); PAH+, pulmonary arterial hypertension-positive patients (right-heart catheterization).
Bossini-Castillo et al. Arthritis Research & Therapy 2012, 14:R273
http://arthritis-research.com/content/14/6/R273
Page 3 of 6
cohort and 13.9 ± 14.4 years in the replication), which
might influence the observed differences.
The PAH+ cohort studied in this report reached a 95%
estimated statistical power to detect an association equiva-
lent to that observed by Wipff et al. within this subgroup
(OR, 0.47, in the comparison between PAH+ SSc patients
and controls of the discovery phase and two replication
steps [11]). Hence, we consider that the lack of replication
observed in our study is unlikely to be caused by a type II
error (false negative) because of a reduced statistical
power. However, autoimmune-associated variants usually
show modest degrees of risk, especially in the case of non-
HLA loci [24]. Wipff et al. reported an OR for KCNA5
rs10744676 polymorphism that was remarkably more pro-
tective than the SSc genetic-association standards for non-
HLA loci (that is, modest ORs between 0.70 and 1). Thus,
we reflect that if the influence of rs10744676 in the SSc-
patient genetic predisposition to PAH is modest, the sta-
tistical power to detect a possible association in the PAH+
cohort analyzed in the present article might be insufficient,
and a possible modest effect of KCNA5 rs10744676 might
be overlooked (Table 1).
In addition, it is established that PAH is more fre-
quent in ACA+ patients [1], and despite the suggestive
association with PAH+ patients, no significant associa-
tion with the ACA+ subphenotype was identified in the
previous SSc study [11] or in this report. This fact is
also consistent with a lack of association of the selected
polymorphism with PAH development.
Although rs10744676 might have a functional role in
KCNA5 expression because of its location in its putative
promoter, no evidence confirms a functional role for
this variant. Therefore, we speculate that the previously
mentioned association with SSc could be the conse-
quence of a tagged causal variant yet to be discovered.
Moreover, because PAH onset time has not been con-
sidered for the analyses, it might act as a confounding
factor in the discrepant results.
Conclusions
In summary, our data do not support an important role
of rs10744676 as a PAH genetic marker in SSc patients.
Additional material
Additional file 1: Genotype and minor allele frequencies of KCNA5
rs10744676 genetic variant in five European cohorts. This file
contains Table S1, showing the genotype and allele distributions of
KCNA5 rs10744676 genetic variant in five European cohorts (2,343 SSc
cases and 2,690 controls).
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